The management of hepatorenal syndrome-acute kidney injury (HRS-AKI): A national survey of hepatology provider practices - PubMed
18 hours ago
- #guideline adherence
- #HRS-AKI
- #hepatology
- Survey of U.S. hepatology providers shows variations in HRS-AKI management compared to guidelines.
- Terlipressin is available at 80% of institutions, more commonly at academic centers.
- Most providers initiate vasoconstrictors after volume expansion trial without renal improvement.
- First-line treatments vary: 49% prefer terlipressin, 44% midodrine/octreotide.
- Nephrology consultation is often delayed until worsening renal function.
- Guideline implementation gaps exist in treatment monitoring and consultation timing.
- Findings aim to inform provider education and updates to clinical guidance.